end-stage renal failure
Conditions
Interventions
four weeks of APS-13SA use, amd for two weeks of the washout period, and then four weeks of NV-13U use
four weeks of NV-13U use, and for two weeks of the washout period, and then four weeks of APS-13
Sponsors
National Defense Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: end-stage renal failure patients with stable outpatient maintenance hemodialysis 60 years or older
Exclusion criteria
Exclusion criteria: hemodialysis patients without any cancer or acute Inflammation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We use conventional polysulfone film (APS - 13SA) and new polysulfone film (NV- 13 U) in 4-week crossover for a hemodialysis patients twice. And we measure solute removal ability (clearance, quantity of removal, removal rate), antithrombotic (activated solidification time, solidification ability) and compare them. | — |
Secondary
| Measure | Time frame |
|---|---|
| We measure a very small amount of albumin in the biocompatible (leukocyte image) dialysis waste fluid of the polysulfone film (APS - 13SA) and new polysulfone film (NV- 13 U) and compare the safety for the elderly patient. | — |
Countries
Japan
Contacts
Public ContactKaori Ishizeki
National Defense Medical College Hospital Department of Blood Purification
Outcome results
None listed